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Background: The Eastern Co-operative Oncology Group (ECOG) 
4599 phase III trial demonstrated that the addition of bevacizumab 
to carboplatin/paclitaxel (CP) signiﬁcantly improved overall survival 
and progression-free survival (PFS) in patients with advanced non-
squamous non-small cell lung cancer (NSCLC) [Sandler et al., NEJM 
2006;355:2542-50]. Cisplatin/gemcitabine (CG) is a combination com-
monly used in Europe and other regions outside of the USA. In order 
to establish the efﬁcacy of bevacizumab in combination with cisplatin-
based doublets, the BO17704 trial investigated the effect of the addition 
of bevacizumab to CG on PFS in patients with advanced NSCLC.
Methods: This randomised, placebo-controlled, multicentre 3-arm 
phase III study compared the efﬁcacy of two doses of bevacizumab in 
combination with CG versus CG plus placebo. The primary endpoint 
was to demonstrate superiority in PFS in both bevacizumab-contain-
ing treatment arms versus the control regimen. Secondary endpoints 
were overall survival, response rate and safety. Eligibility criteria were 
histologically or cytologically documented previously untreated locally 
advanced, metastatic or recurrent non-squamous NSCLC; ECOG per-
formance status 0-1; adequate haematological, renal and liver function; 
no brain metastases; no history of recent CTC grade ≥2 haemoptysis. 
Between February 2005 and August 2006, a total of 1,043 patients were 
randomised 1:1:1 to three treatment groups. One group received up to 
6 cycles of C 80mg/m2 on day 1 and G 1,250mg/m2 on day 1 and day 
8 every 3 weeks plus placebo (n=347). The second group received CG 
chemotherapy plus bevacizumab at a dose of 7.5mg/kg every 3 weeks 
(n=345), and the third group received CG chemotherapy plus beva-
cizumab at a dose of 15mg/kg every 3 weeks (n=351). Bevacizumab 
was to be administered until disease progression for both bevacizumab 
arms. Data cut-off was two months after the last patient was enrolled.
Results: Bevacizumab at a dose of 7.5 or 15mg/kg every 3 weeks in 
combination with CG chemotherapy signiﬁcantly prolonged PFS in pa-
tients with advanced NSCLC when compared with CG chemotherapy 
plus placebo. The treatment effects observed in the two bevacizumab-
containing arms were similar. No new safety signals associated with the 
use of bevacizumab were observed for either bevacizumab dose in this 
clinical setting.
Conclusions: The trial met its primary endpoint. Final efﬁcacy and 
safety results for each arm will be presented at the meeting.
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Background: Acquired resistance to geﬁtinib in NSCLC patients 
with somatic activating EGFR mutations has been associated with 
the development of a secondary T790M mutation in about 50% of the 
patients. The mechanisms for acquired resistance in the remaining 
tumors are still unknown. Heat shock protein 90 (Hsp90) is a molecular 
chaperone that plays a key role in the conformational maturation of 
oncogenic signaling proteins and has become an exciting therapeutic 
target for the treatment of cancer. IPI-504, the highly soluble hydro-
quinone hydrochloride derivative of 17-AAG, was synthesized as an 
Hsp90 inhibitor with favorable pharmaceutical properties. Herein, we 
explored new therapeutic strategies overcoming the EGFR T790M and 
non-T790M geﬁtinib-resistance mechanisms. Methods and Results: We 
have developed geﬁtinib-resistant (GR) clones from geﬁtinib-hyper-
sensitive EGFR L858R mutant (H3255) and EGFR exon 19 deletion 
(del E746_A750) mutant (HCC827) NSCLC cell lines by exposing 
them to increasing concentrations of geﬁtinib in vitro. Analyses of the 
resistant cells demonstrate that H3255 GR contain an EGFR T790M 
mutation which is not observed in HCC827 GR cells. We investigated 
the effects of IPI-504 on cells according to the mechanism of resistance 
to geﬁtinib; KRAS mutation (A549 and H441), EGFR T790M mutation 
(H1975 and H3255GR) and non-T790M mutation (HCC827GRs). In 
time course experiments, mutant EGFR proteins in H1975, H3255GR 
and HCC827GRs were depleted after only 6 hrs of exposure to 100 
nM IPI-504, while diminution of wild-type EGFR in A549 and H441 
was less substantial. However, several client proteins for Hsp90 were 
equally affected among these cell lines. Exposure to IPI-504 showed 
dose and time dependent growth inhibition exhibiting IC50 values for 
cell viability at 72 h that ranged from 41 - 293nM. All cell lines tested 
were found to be sensitive to IPI-504 regardless of geﬁtinib-resistance 
mechanisms. When geﬁtinib was combined, IPI-504 also showed 
synergism with Combination Indices (CI) at the IC50 and further stud-
ies are ongoing to evaluate for potential synergy with geﬁtinib. Flow 
cytometric Tunel assay and ﬂuorescent-based casspase 3/7 in H1975, 
H3255GR and HCC827GR with mutant EGFR showed that the 48 hr 
treatment with 1.0uM IPI-504 caused an increase in sub-G1 fraction 
and apoptosis. 
Conclusions: These data support the conclusion that mutational activa-
tion of EGFR is associated with dependence on Hsp90 for stability. 
Taken together, IPI-504 represents a novel strategy for the treatment 
of NSCLC patients having EGFR T790M or non-T790M geﬁtinib-re-
sistance mechanism and suggests an important implication for clinical 
development.
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Study Objective: Protocols using indction chemotherapy for advanced 
lung cancer are more frequently used with the hope that surgery can be 
performed after the cancer is downstaged. The current restaging mo-
dalities either have a low diagnostic accuracy (computed tomography) 
or can be technically difﬁcult (Re-, mediastinoscopy). Endobronchial 
ultrasound guided TBNA is an excellent tool for mediastinal lymph 
node staging and may have a role in restaging also. 
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Methods and Patients: Patients with NSCLC and proven ipsilateral or 
subcarinal lymph node metastases (N2 disease, 3A disease stage) who 
had been treated with induction chemotherapy and showing at least 
stable disease or partial response on CT imaging underwent mediastinal 
restaging by EBUS-TBNA. This was followed by surgical resection of 
the tumour with lymph node dissection. 
Results: 124 Patients (51 male, 73 female, mean age 58 y.) had either 
a partial response (n=66) or stable disease (n=58) based on sequential 
CT scans of the thorax. After restaging all patients underwent surgery. 
Overall the sensitivity, speciﬁcity, positive predictive value, negative 
predictive value and diagnostic accuracy of EBUS-TBNA for medias-
tinal re-staging following induction chemotherapy were 76%, 100%, 
100%, 20% and 77% respectively. 
Conclusions: EBUS-TBNA is an accurate, safe and minimally invasive 
diagnostic technique for the restaging of mediastinal lymph nodes after 
induction therapy in NSCLC. It’s routine use for this purpose should be 
considered.
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Background: CT-guided Transthoracic Needle Biopsy (TNB) is 
commonly used in the diagnosis of thoracic lesions. PNX is the most 
common complication of this procedure with a reported rate from 8 
to 61%, with few cases requiring chest tube insertion. The aim of this 
prospective study was to estimate the risk of PNX in patients undergo-
ing CT-guided lung biopsy and to determine which factors affect its 
occurrence. 
Methods: Between November 2002 and August 2006, 708 TNB were 
performed in 691 patients with a CT-documented central or peripheral 
pulmonary lesion: 75% were males, median age was 67 years (range 
29-87). Risk factors for PNX were classiﬁed in three groups: patient-
related (age, sex, emphysema around the lesion), lesion-related (size, 
depth, location, presence of cavitations and/or pleural tags, chest wall 
invasion, pleural thickening, ﬁssure/atelectasis in the needle path) 
and procedure-related (patient position, needle puncture side, chest 
wall thickness, dwell-time (time between pleural puncture and needle 
removal), needle-pleural angle (smallest angle of the needle with the 
pleura), number of cutting specimens, number of pleural passages. 
Lesion depth was measured as the length of the aerated lung from the 
surface of pleura to the edge of the lesion. Lesion size was considered 
the average lesion diameter in two axial planes. Immediately after 
the procedure, a CT scan was obtained to control presence of PNX; 
patients were followed-up for 4 hours and chest radiographs were 
obtained at the end of this period. All variables were analysed by Chi-
square and Student t test for occurrence of PNX and p value < 0.05 was 
considered as statistically signiﬁcant. 
Results: PNX occurred in 181/708 procedures (25.6%) and tube 
insertion was required in 18 cases (2.5%). An higher lesion depth was 
the most signiﬁcant predictor of PNX (p=0.002): the mean depth of 
lesions from the pleural surface was 27.4 mm in patients with PNX 
and 17.2 mm in patients without PNX. There were 216 lesions in direct 
contact with the pleura: PNX developed in only 20 (9.2%). Among 
lesion related variables, chest wall invasion (p<0.03) and lesion size 
(p=0.03; 31.7 mm in group with vs 38.9 mm in group without PNX) 
showed correlation. A greater incidence of PNX was seen in smaller 
lesions: for lesions 1 cm or smaller, the rate was 35%. Among patient 
and procedure variables, age (68 vs 64 years, p<0.03) and number of 
cutting specimens (p=0.01) were associated with an increased risk of 
PNX. Number of pleural punctures, needle-pleural angle, dwell-time, 
lesion location, presence of emphysema along needle path and sex did 
not effect risk of PNX. 
Conclusion: In consecutive cases of CT-guided TNB the length of the 
lung parenchyma crossed during the biopsy is the predominant risk fac-
tor for PNX. The risk of PNX was also related to the mean lesion size, 
age, presence of chest wall invasion and number of cutting specimens.
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Accurate staging allows assessment of prognosis and determines 
treatment plans in patients with lung cancer. Evaluation of mediastinal 
lymphnodes (LN) is crucial to determine the stage of the cancer. Only 
up to 20% of patients with lung cancer present in early stage allow-
ing surgical treatment. Current mediastinal staging methods include 
mediastinoscopy (MS) and CT-PET. MS with the sensitivity of 70% 
- 95% is the gold standard in evaluation of LN and provides access to 
LN stations: 2, 3, 4, and 7. MS is an invasive procedure, which requires 
general anaesthetic, carries minimal, nonetheless, mortality and for 
technical reasons it is usually done only once. There is therefore a need 
to develop less invasive techniques allowing an adequate evaluation 
of mediastinal LN. CT-PET has been shown to be useful in predicting 
malignant mediastinal LN with a high negative predictive value (97%) 
but with only moderate positive predictive value (75%). However, 
CT-PET does not provide histological diagnosis. Real-time Endobron-
chial Ultrasound FNA with Doppler facilities (EBUS) provides a safe 
alternative to MS in staging of lung cancer. EBUS allows easy access 
to mediastinal and hilar LN stations: 2, 3, 4, 7, 10 and 11. EBUS is 
performed as an out-patient procedure in conjunction with standard 
bronchoscopy under conscious sedation.
We have performed 300 EBUS procedures from May 2005 until Mar 
2007 using an OLYMPUS Ultrasonic Linear Bronchoscope BF-UM40. 
Tissue samples were obtained using 22G needle and processed using a 
thin layer technique and stained with PAP. Any residual material was 
processed as a cell block.
There were 153 positive aspirations for malignancy. In 124 cases we 
diagnosed Non Small Cell Lung Cancer, 23 Small Cell Lung Cancer 
and 6 mixed tumours. The most frequently (in order) sampled LN sta-
tions were: 7, 4, 10, 11, 2 and 3. There were 7 false negative results. 
87 primary tissue diagnoses were obtained and 137 MS were avoided. 
There were no complications. Calculated EBUS sensitivity was 94% 
